Eliana Clark Sells $8.36K of Intellia Therapeutics Inc (NTLA) — SEC Form 4, Mar 03, 2026

Open-Market Net Sale · SEC Form 4
−$8,364

Equity position changed by +7.7%

Reporting Owner
Eliana Clark
CTO
TXN 2026-03-02 · FILED 2026-03-03
Equity Position 94.5K sh 87,725 → 94,471
Equity Change +7.7% shares held after vs before
Filing Lag 1 business day within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership

Intellia Therapeutics Inc

NTLA CIK 0001652130
All Intellia Therapeutics Inc insider activity
Filing Date
2026-03-03
Report Date
2026-03-03
Accession No.
0001193125-26-088241
Accepted At
2026-03-03 21:16 UTC
Reporting Owner
Name Relationship
Eliana Clark CIK 0001914448
CTO
Eliana Clark at Intellia Therapeutics Inc Full insider history
Bought (12 mo) —
Sold (12 mo) $95,997
More from this insider at Intellia Therapeutics Inc
2026-01-07 Sell -$87,633 View
2025-07-03 Sell -$10,036 View
2025-03-04 Sell -$6,104 View
2025-01-06 Sell -$97,089 View
2024-07-03 Sell -$9,287 View
All filings by this insider at Intellia Therapeutics Inc
Non-Derivative Securities Transactions
Title Date Type Shares Price Net Total Post-Txn Ownership
Common StockF1 2026-03-01 A - Award/Grant 7,353 A $0.00 — 94,471 Direct
Common StockF2 2026-03-02 S - Sale 607 D $13.78 -$8,364 93,864 Direct
Derivative Securities Transactions
Title Strike Date Type Shares Price Expiration Underlying Ownership
Stock Option (right to buy)F3 $13.78 2026-03-01 A - Award/Grant 10,505 A $0.00 2036-02-29 10,505 Common Stock Direct
Footnotes (3)
F1
Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Show more
F2
Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on March 1, 2026, and does not represent a volitional trade by the Reporting Person. Show more
F3
This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. Show more

Related filings at Intellia Therapeutics Inc

Institutional Holders
13F holders · Jun 30, 2026 328 institutional managers reporting a position
Largest by reported value
  1. Ark Investment Management Llc $286M
  2. Black Rock, Inc. $261M
  3. State Street Corporation $156M
5%+ Holders · 13D/G 5 filers

Latest Schedule 13D/G per filer; stakes the filer reported closed are left out.

Other insiders at Intellia Therapeutics Inc
All Intellia Therapeutics Inc insider activity
GET /v1/forms/4/0001193125-26-088241 API docs
View Original SEC Filing